


Identifying Potential Challenges During the Diagnostic Journey





RELATED QUESTIONS TO CONSIDER

Biopsy

Do you work collaboratively with the MDT to identify lesions to sample and potentially assess for tissue adequacy?³

- Yes
 No

Processing

Do you consistently limit cold ischemia time?³

- Yes
 No

Do you consider downstream testing when choosing fixation methods?³

- Yes
 No

Do you divide tissues into more than 1 cassette?³

- Yes
 No

Do you perform microdissections to remove non-tumor or necrotic tissue?^{3,6}

- Yes
 No

Ordering

Have you established a common language with consistent terminology between other members of the MDT?^{9,10}

- Yes
 No

Have you considered minimizing the number of available testing platforms at your institution?¹²

- Yes
 No

When was the last time you reviewed and incorporated recommendations from published guidelines into your SOPs and institution forms?¹¹

Date(s):

Testing

Have you checked the testing limitations for all assays?¹⁰

- Yes
 No

How is fusion testing performed at your institution?¹⁰

Do you consistently have biomarker test results available by your patients first visit?¹⁵

- Yes
 No

At your institute, are the reports readable and searchable across platforms?¹⁸

- Yes
 No

At your institute, has your EHR been updated to be compatible with your LIS (or vice versa)?¹⁸

- Yes
 No

Reports and Treatment Decisions

Are precision oncology knowledge databases accessed when needed to assess which alterations are clinically actionable?¹⁰

- Yes
 No

Do you use synoptic style reporting in your pathology reports?^{18,21}

- Yes
 No

Do you use headlines to emphasize key findings in your pathology reports?¹⁸

- Yes
 No

Do you utilize CAP electronic Cancer Checklists?¹⁸

- Yes
 No

Are pathology reports linked to all addendum reports in the EHR at your institution?¹⁸

- Yes
 No

Do clinicians receive notifications when an addendum report has been entered?¹⁸

- Yes
 No

REFERENCES

1. Roberts MC et al. *JCO Precis Oncol.* 2021;5:701-709. 2. Bhamidipati D et al. *NPJ Precis Oncol.* 2021;5(1):94. 3. De Las Casas LE, Hicks DG. *Am J Clin Pathol.* 2021;155(6):781-792. 4. Roy-Chowdhuri S et al. *Arch Pathol Lab Med.* 2020;144(8):933-958. 5. Costa C et al. *Cancer Cytopathol.* 2018;126(9):767-772. 6. Jennings LJ et al. *J Mol Diagn.* 2017;19(3):341-365. 7. Plotkin E et al. *J Clin Oncol.* 2019;37(suppl 27):49. 8. Lubin IM et al. *J Mol Diagn.* 2008;10:459-468. 9. Martin NA et al. *JCO Precis Oncol.* 2021;5:PO.21.00027. 10. Chakravarty D et al. *J Clin Oncol.* 2022;40(11):1231-1258. 11. Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. *Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine.* Graig LA, Phillips JK, Moses HL, editors. Washington (DC): National Academies Press (US); 2016. 12. El-Deiry WS et al. *CA Cancer J Clin.* 2019;69(4):305-343. 13. Pennell NA et al. *Am Soc Clin Oncol Educ Book.* 2019;39:531-542. 14. Anand K et al. *Clin Lung Cancer.* 2020;21(5):437-442. 15. Lim C et al. *Ann Oncol.* 2015;26(7):1415-1421. 16. Pennell NA et al. *JCO Precision Oncology.* 2019;3:1-9. 17. Yu TM et al. *Clin Lung Cancer.* 2019;20(1):20-29. 18. ACCC CAP Precision Medicine: Integration of Pathology with the Cancer Care Team. https://www.accc-cancer.org/docs/projects/landscape-of-pathology/pathology-coordinating-reporting.pdf?sfvrsn=fa5ddb9e_2. Accessed November 9, 2022. 19. Brown NA, Elenitoba-Johnson KSJ. *Annu Rev Pathol Mech Dis.* 2020;15:97-121. 20. ACCC CAP Precision Medicine: Integration of Pathology with the Cancer Care Team. https://www.accc-cancer.org/docs/projects/landscape-of-pathology/pathology-patient-centered-care.pdf?sfvrsn=8173e1cb_2. Accessed November 9, 2022. 21. CAP Definition of Synoptic Reporting. https://documents.cap.org/documents/synoptic_reporting_definition_examples_v4.0.pdf. Accessed November 9, 2022. 22. Valenstein PN. *Arch Pathol Lab Med.* 2008;132:84-94. 23. Nussinov R et al. *PLoS Comput Biol.* 2019;15(3):e1006658. 24. Li M et al. *J Mol Diagn.* 2017;19(1):4-23.

SUMMARY



Molecular diagnostics is a multistep process requiring collaboration among distinct disciplines³



Successful biomarker testing depends on key factors:

- Testing tissue of sufficient quantity and quality¹
- Ordering process for actionable biomarkers¹⁰
- Use of appropriate tests¹⁰
- Access to clear and searchable report data¹⁸



Multiple professional societies have developed resources to assist with testing barriers^{9,10,11}



Are you interested in learning more about **Precision Medicine?**



GO TO OUR WEBSITE!



You'll find knowledge checks, additional resources, a digital version of this and other chapters, and more

www.hcp.novartis.com/precision-medicine



Looking to speak to a Precision Medicine Liaison? Scan this QR code

www.hcp.novartis.com/precision-medicine/contact-us

